Michelle Dalton

Michelle Dalton

Contributing Writer

Michelle Dalton, ELS, is an award-winning journalist who founded Dalton & Associates Medical Writing in 2006. She has spent the past 17 years writing primarily about ophthalmology, covering everything from the business of ophthalmology to the latest in pharmacologic and technology advances.

  • All
  • Deals
  • Devices and Diagnostics
  • Digital
  • Genetics
  • Pharma
OIS@ASRS Reporter's Notebook: Three Things Learned at OIS@ASRS About What Funders Want, Going Global, and AI

OIS@ASRS Reporter’s Notebook: Three Things Learned at OIS@ASRS About What Funders Want, Going Global, and AI

CHICAGO – This year’s OIS@ASRS jam-packed into one day presentations from early and late-stage retinal treatment developers, panels from key opinion leaders in industry and ...
Read More
Novartis’ New Head of Ophthalmology Lays Out Lofty Goals Days Before Xiidra Deal

Novartis’ New Head of Ophthalmology Lays Out Lofty Goals Days Before Xiidra Deal

VANCOUVER – Novartis is one of the world’s largest ophthalmic pharmaceutical companies, with $4.6 billion in assets as part of the Medicines division, yet some ...
Read More
Protocol V, LEAVO Among Retina Highlights at ARVO

Protocol V, LEAVO Among Retina Highlights at ARVO 2019

VANCOUVER – Leave it to ARVO 2019 – the Association for Research in Vision and Ophthalmology – to keep attendees waiting until mid-evening to hear ...
Read More
How Green Surgery Practices Are Reducing Greenhouse Gasses and Waste, and Cutting Costs

How Green Surgery Practices Are Reducing Greenhouse Gasses and Waste, and Cutting Costs

Surgery in most high-income countries generates large quantities of waste. For instance, single-use disposable instruments are often used in a variety of surgery settings, but ...
Read More
Chasing Presbyopia Utopia

Chasing Presbyopia Utopia: Four Innovators and Their Search for Ophthalmology’s ‘Holy Grail’

The numbers can be overwhelming: 1.8 billion people globally were living with presbyopia in 2015, 826 million of whom had near vision impairment because they ...
Read More
What Relaxed Gene Therapy Oversight Means

Putting Relaxed NIH, FDA Oversight of Gene Therapies into Perspective

The first human gene therapy trial started in 1990, and over the course of that decade a multitude of questions about the safety and efficacy ...
Read More
MIGS Minus One: What’s Next?

MIGS Minus One: What’s Next?

With Alcon’s voluntary withdrawal in late August of the CyPass MicroStent due to safety concerns, many have been wondering how the rest of the class ...
Read More
Dry Eye Panel Sees Promising Path Ahead

How Newer Diagnostics and Devices Are Making Dry Eye Treatments an Easier Sell

WASHINGTON, DC – Treating flairs and fluctuations while employing steroid tapering for the treatment of dry eye was the hot topic during the dry eye ...
Read More
Integrins Gain Traction in Ophthalmology

With Integrins, Necessity Really is the Mother of all Invention

Stopping growth factors that create damage in the eye has proven lucrative. Lucentis (ranibizumab, Roche/Genentech) achieved sales of $1.8 billion in 2016 outside the US ...
Read More
Dry Eye Newbie Xiidra Grabs Large Market Share

Dry Eye Newbie Xiidra Grabs Large Market Share

During the run-up to the launch of Shire’s dry eye drug Xiidra (lifitegrast), it seemed as though everyone was wondering what kind of threat – ...
Read More

Iconic Leader Allergan Has No Plans to Slow Down

CHICAGO—This year’s OIS Industry Tribute celebrated one of the best-known names in ophthalmology: Allergan. The Dublin-based company is one that “we rely on for innovation ...
Read More
Aerie’s positive data keeps Wall Street happy

Aerie’s Positive Data Keep Wall Street Happy

Earlier this month, Aerie Pharmaceuticals filed its first NDA for once-daily Rhopressa (netarsudil) and released top-line data from its once-daily Roclatan (Rhopressa and latanoprost) Mercury ...
Read More